![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Bibliography
- Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012;161(2):461–72
- Verhoef JJ, Carpenter JF, Anchordoquy TJ, Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today 2014. 10.1016/j.drudis.2014.08.015
- Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010;99(6):2557–75
- Sugahara K, Kitagawa H. Heparin and heparan sulfate biosynthesis. IUBMB Life 2002;54(4):163–75
- Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002;41(3):391–412
- Pikas DS, Li JP, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998;273(30):18770–7
- Harris EN, Weigel PH. The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates a, c, and d bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and cs-e. Glycobiology 2008;18(8):638–48
- DeAngelis PL. Microbial glycosaminoglycan glycosyltransferases. Glycobiology 2002;12(1):9R–16R
- Sismey-Ragatz AE, Green DE, Otto NJ, et al. Chemoenzymatic synthesis with distinct Pasteurella heparosan synthases: monodisperse polymers and unnatural structures. J Biol Chem 2007;282(39):28321–7